4D PHARMA PLC
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.4dpharmaplc.com
Clinical Trials
13
Active:5
Completed:2
Trial Phases
3 Phases
Phase 1:9
Phase 2:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (69.2%)Phase 2
3 (23.1%)Not Applicable
1 (7.7%)Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
Phase 1
Withdrawn
- Conditions
- Idiopathic Parkinson Disease
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT05832775
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
Phase 2
Withdrawn
- Conditions
- Urothelial Carcinoma
- Interventions
- Biological: Avelumab 20 mg/mL Intravenous Solution (IV)
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT05107427
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT04363372
- Locations
- 🇬🇧
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Hypofractionated Preoperative Radiation
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 13
- Registration Number
- NCT04193904
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of MRx-4DP0004 in Asthma
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 34
- Registration Number
- NCT03851250
- Locations
- 🇺🇸
OHSU Allergy and Clinical Immunology Clinic, Portland, Oregon, United States
🇬🇧Bradford Teaching Hospital, Bradford, West Yorkshire, United Kingdom
🇬🇧4D Site Leicester, Leicester, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found